Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
Stopped UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.
Conditions
- Salivary Gland Dysfunction
- Xerostomia
- Head and Neck Cancer
Interventions
- DRUG: Everolimus
- OTHER: Laboratory Biomarker Analysis
- OTHER: Survey Administration
Sponsor
University of Arizona
Collaborators